Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to “Hold” at Wall Street Zen

Amylyx Pharmaceuticals (NASDAQ:AMLX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other equities research analysts have also issued reports about the company. Bank of America raised their target price on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Stifel Nicolaus assumed coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $21.00 price objective on the stock. HC Wainwright increased their target price on shares of Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Amylyx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $19.56.

Amylyx Pharmaceuticals Trading Down 1.8%

Shares of Amylyx Pharmaceuticals stock opened at $13.85 on Friday. The business has a 50-day moving average price of $13.94 and a two-hundred day moving average price of $13.22. Amylyx Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $17.49. The company has a market cap of $1.53 billion, a P/E ratio of -8.94 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Equities research analysts forecast that Amylyx Pharmaceuticals will post -2.2 EPS for the current fiscal year.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 1,995 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the transaction, the chief executive officer owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. This trade represents a 0.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Frates sold 3,326 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total value of $36,951.86. Following the completion of the transaction, the chief financial officer owned 177,104 shares of the company’s stock, valued at $1,967,625.44. This represents a 1.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 151,203 shares of company stock worth $2,028,385. 12.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. purchased a new position in shares of Amylyx Pharmaceuticals in the fourth quarter worth approximately $25,000. Aster Capital Management DIFC Ltd purchased a new stake in Amylyx Pharmaceuticals during the third quarter valued at approximately $48,000. Caitong International Asset Management Co. Ltd increased its position in Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after buying an additional 3,493 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at $28,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after acquiring an additional 1,890 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals News Roundup

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (now -$0.34 per quarter in 2026 vs prior deeper losses) and materially boosted multi‑year outlook (FY2029 and FY2030 upgrades) while maintaining a “Buy” rating and a $34 price objective — a clear vote of confidence on longer‑term upside.
• Positive Sentiment: Avexitide remains the company’s key near‑term catalyst: Phase 3 LUCIDITY topline data due Q3 2026; management is viewed as well‑funded (reported cash runway cited ~ $317M into 2028), which supports commercialization planning if results are positive. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Positive Sentiment: New coverage initiated by Stifel Nicolaus can increase visibility and institutional interest, a constructive development for liquidity and analyst debate. Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus
• Neutral Sentiment: Q4 2025 earnings call highlighted strategic advances and the company slightly beat EPS expectations (reported -$0.30 vs -$0.31 consensus), but near‑term profitability remains a multi‑quarter issue. Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports in the filings provided show zero or nonsensical values (likely reporting artifacts) and so offer no clear signal on current positioning.
• Negative Sentiment: Management discontinued development of AMX0035 for progressive supranuclear palsy (PSP), narrowing the near‑term pipeline and prompting at least one downgrade (from “Strong Buy” to “Buy”); loss of a program can reduce optionality and may weigh on sentiment until avexitide data arrives. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.